These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19046736)

  • 1. Obesity-related cardiometabolic complications.
    Cannon CP
    Clin Cornerstone; 2008; 9(1):11-9; discussion 20-2. PubMed ID: 19046736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular disease and modifiable cardiometabolic risk factors.
    Cannon CP
    Clin Cornerstone; 2008; 9(2):24-38; discussion 39-41. PubMed ID: 19410160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapies for cardiometabolic risk reduction and implications for clinical practice.
    Watson KE
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S37-42. PubMed ID: 17934393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
    Ferdinand KC
    J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular disease and modifiable cardiometabolic risk factors.
    Cannon CP
    Clin Cornerstone; 2007; 8(3):11-28. PubMed ID: 18452839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleiotropic effects of rimonabant: clinical implications.
    Després JP
    Curr Pharm Des; 2009; 15(5):553-70. PubMed ID: 19199981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
    Després JP; Ross R; Boka G; Alméras N; Lemieux I;
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
    Ruilope LM; Després JP; Scheen A; Pi-Sunyer X; Mancia G; Zanchetti A; Van Gaal L
    J Hypertens; 2008 Feb; 26(2):357-67. PubMed ID: 18192851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
    Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
    JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association.
    Bays HE; Toth PP; Kris-Etherton PM; Abate N; Aronne LJ; Brown WV; Gonzalez-Campoy JM; Jones SR; Kumar R; La Forge R; Samuel VT
    J Clin Lipidol; 2013; 7(4):304-83. PubMed ID: 23890517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of the obese patient in primary care: targeting and meeting goals and expectations.
    Bray G; Look M; Ryan D
    Postgrad Med; 2013 Sep; 125(5):67-77. PubMed ID: 24113665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
    Chapman MJ; Sposito AC
    Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidemia and glucose dysregulation in overweight and obese patients.
    LeRoith D
    Clin Cornerstone; 2007; 8(3):38-52. PubMed ID: 18452841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    Després JP; Golay A; Sjöström L;
    N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance.
    Masuo K; Rakugi H; Ogihara T; Esler MD; Lambert GW
    Curr Diabetes Rev; 2010 Mar; 6(2):58-67. PubMed ID: 20034369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity as a cardiovascular risk factor.
    Sowers JR
    Am J Med; 2003 Dec; 115 Suppl 8A():37S-41S. PubMed ID: 14678864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus.
    Rader DJ
    Am J Med; 2007 Mar; 120(3 Suppl 1):S12-8. PubMed ID: 17320517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of angiotensin II receptor blockers on insulin resistance.
    Ragonesi PD
    Hypertens Res; 2010 Aug; 33(8):778. PubMed ID: 20555329
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.